Applied Therapeutics, Inc. (NASDAQ:APLT) CFO Sells $73,353.60 in Stock

Applied Therapeutics, Inc. (NASDAQ:APLTGet Free Report) CFO Leslie D. Funtleyder sold 16,980 shares of the company’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $4.32, for a total value of $73,353.60. Following the completion of the sale, the chief financial officer now owns 291,441 shares in the company, valued at approximately $1,259,025.12. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Applied Therapeutics Price Performance

NASDAQ:APLT opened at $5.27 on Thursday. The business’s 50-day moving average is $4.64 and its two-hundred day moving average is $4.28. The firm has a market capitalization of $602.19 million, a PE ratio of -2.86 and a beta of 1.88. Applied Therapeutics, Inc. has a 12 month low of $1.18 and a 12 month high of $9.39.

Applied Therapeutics (NASDAQ:APLTGet Free Report) last announced its earnings results on Thursday, May 9th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $10.00 million. Equities analysts anticipate that Applied Therapeutics, Inc. will post -0.59 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. SVB Leerink began coverage on shares of Applied Therapeutics in a research note on Thursday, February 22nd. They issued an “outperform” rating and a $12.00 price objective on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $12.00 price objective on shares of Applied Therapeutics in a research report on Thursday, April 11th. Citigroup upped their price target on shares of Applied Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. Leerink Partnrs restated an “outperform” rating on shares of Applied Therapeutics in a research note on Thursday, February 22nd. Finally, UBS Group lifted their price objective on Applied Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $11.00.

Get Our Latest Stock Analysis on Applied Therapeutics

Institutional Trading of Applied Therapeutics

Several large investors have recently bought and sold shares of the company. AIGH Capital Management LLC boosted its stake in shares of Applied Therapeutics by 109.1% in the fourth quarter. AIGH Capital Management LLC now owns 1,659,039 shares of the company’s stock valued at $5,558,000 after purchasing an additional 865,689 shares during the period. Worth Venture Partners LLC boosted its position in Applied Therapeutics by 112.9% in the 4th quarter. Worth Venture Partners LLC now owns 412,981 shares of the company’s stock valued at $1,383,000 after buying an additional 219,008 shares during the last quarter. Vestal Point Capital LP acquired a new stake in shares of Applied Therapeutics during the fourth quarter valued at about $13,919,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Applied Therapeutics during the third quarter worth about $1,139,000. Finally, Armistice Capital LLC purchased a new stake in Applied Therapeutics during the 3rd quarter worth approximately $8,466,000. Institutional investors and hedge funds own 98.31% of the company’s stock.

About Applied Therapeutics

(Get Free Report)

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

Featured Stories

Insider Buying and Selling by Quarter for Applied Therapeutics (NASDAQ:APLT)

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.